Abstract
The ATP binding cassette (ABC) transporter family is ubiquitous in eukaryotes, specifically in vertebrates, and plays a crucial role in energy homeostasis, cell signaling, and drug resistance. Accumulating evidence indicates that some ABC transporters contribute to cancer cell proliferation and tumor progression; however, relatively little is known about the behavior of the ABC transporter family in hepatocellular carcinoma (HCC). By analyzing two public transcriptomic databases, we evaluated the effect of genes in the ABC transporter family on HCC prognostic prediction; ABCC6 was selected for further study. Notably, ABCC6 was found to be downregulated in HCC tissues and correlated with favorable outcomes in patients with HCC. Moreover, ABCC6 knockdown not only significantly promoted cell proliferation in vitro and in vivo, but also inhibited cell cycle arrest and cell apoptosis. Transcriptome analysis revealed that ABCC6 depletion enhanced the “mitotic cell cycle” and “DNA replication” pathways, and suppressed the “PPAR signaling pathway”. Further investigation demonstrated that PPARα, one of the key regulators in peroxisome metabolism, is located downstream of ABCC6. In summary, our study provides profound insights into the behavior of ABC transporter family genes in various HCC cohorts, identifies ABCC6 as a biomarker for early-stage HCC diagnosis, and offers experimental basis for further investigations of targeting ABCC6 in the treatment of patients with HCC.
Highlights
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and accounts for approximately 85% of primary liver cancers [1]
Eight ATP binding cassette (ABC) transporter genes (e.g., ABCA8, ABCC6, and ABCC9) were significantly downregulated in prostate cancer tissues compared with noncancerous tissues [26]
Transporter family members in the Cancer Genome Atlas (TCGA) and GSE14520 datasets, and found that ABCC6 is significantly downregulated in hepatocellular carcinoma (HCC) tumor tissues and correlated with favorable outcomes in patients with HCC
Summary
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and accounts for approximately 85% of primary liver cancers [1]. Risk factors for HCC include hepatitis B virus infection, cirrhosis, non-alcoholic fatty liver disease, excessive alcohol consumption, autoimmune disease, and accumulation of reactive oxygen species (ROS) [3, 4]. ABCC6 Knockdown Regulates PPARa in HCC improved the 5-year survival of patients with HCC [5]. Some ABC transporters, such as ABCC1, ABCG2, and ABCB1, are highly efficient at extruding drugs from cancer cells, resulting in substantial multidrug resistance [8]. Accumulating evidence indicates that some ABC transporters contribute to cancer cell proliferation and tumor progression [6, 7]. ABCC4 knockdown induces cell cycle arrest and apoptosis in acute myeloid leukemia [9]. Overexpression of ABCC1 correlates with reduced overall survival in patients with neuroblastoma [10].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.